Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorIcoz, Kutay
dc.contributor.authorGercek, Tayyibe
dc.contributor.authorMurat, Aysegul
dc.contributor.authorOzcan, Servet
dc.contributor.authorUnal, Ekrem
dc.date.accessioned2019-07-30T09:41:05Z
dc.date.available2019-07-30T09:41:05Z
dc.date.issued2019en_US
dc.identifier.citationBIOTECHNOLOGY PROGRESS Volume: 35 Issue: 1 Article Number: UNSP e2737 DOI: 10.1002/btpr.2737en_US
dc.identifier.issn8756-7938
dc.identifier.issneISSN: 1520-6033
dc.identifier.otherAccession Number: WOS:000458312200028
dc.identifier.otherDOI: 10.1002/btpr.2737
dc.identifier.otherArticle Number: UNSP e2737
dc.identifier.urihttp://acikerisim.agu.edu.tr/xmlui/handle/20.500.12573/76
dc.descriptionAuthors acknowledge The Scientific and Technological Research Council of Turkey (TUBITAK Project No: 115E020) for financial support and Prof. Ahmet Eken and Prof. Musa Karakukcu from Erciyes University for valuable discussions for the cell line and immunomagnetic separation related issues. Ekrem Unal acknowledges Gilead Research Scholarship program.en_US
dc.description.abstractOne way to monitor minimal residual disease (MRD) is to screen cells for multiple surface markers using flow cytometry. In order to develop an alternative microfluidic based method, isolation of B type acute lymphoblastic cells using two types of antibodies should be investigated. The immunomagnetic beads coated with various antibodies are used to capture the B type acute lymphoblastic cells. Single beads, two types of beads and surface immobilized antibody were used to measure the capture efficiency. Both micro and nanosize immunomagnetic beads can be used to capture B type acute lymphoblastic cells with a minimum efficiency of 94% and maximum efficiency of 98%. Development of a microfluidic based biochip incorporating immunomagnetic beads and surface immobilized antibodies for monitoring MRD can be an alternative to current cost and time inefficient laboratory methods. (c) 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2737, 2019en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) - 115E020en_US
dc.language.isoengen_US
dc.publisherWILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USAen_US
dc.relation.ispartofseriesBIOTECHNOLOGY PROGRESS;Volume: 35 Issue: 1
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectB type acute lymphoblastic leukemia cellsen_US
dc.subjectcell capture efficiencyen_US
dc.subjectminimal residual diseaseen_US
dc.subjectimmunomagnetic separationen_US
dc.subjecttwo antibody sortingen_US
dc.titleCapturing B type acute lymphoblastic leukemia cells using two types of antibodiesen_US
dc.typearticleen_US
dc.contributor.departmentAGÜ, Mühendislik Fakültesi, Elektrik & Elektronik Mühendisliği Bölümüen_US
dc.contributor.institutionauthor
dc.identifier.doi10.1002/btpr.2737
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster